This session will highlight some of the many recent advances in a discussion of best practices for the treatment of Parkinson's disease and related disorders. Parkinson’s disease is extremely prevalent in skilled nursing environments and will increase in prevalence as the adult population ages. Treatment approaches continue to focus on dopaminergic medications along with related therapies. However, there have been notable advances in improving bioavailability of currently available medications including recently Federal Drug Administration approved formulations of carbidopa/levodopa in addition to other controlled-released formulations of previously available medications including apomorphine, amantadine and rasagiline. There is also an increased recognition of the role of nonmotor symptoms in quality of life for individuals living with Parkinson’s. Nonmotor symptoms do not typically respond well to dopaminergic medications but there have been a number of breakthroughs including a medication specifically for Parkinson’s disease psychosis (working on the serotonin system instead of the dopaminergic suppression of first-generation antipsychotics).
There is also a new medication approach for neurogenic orthostatic hypotension as well as treatments for other nonmotor symptoms including drooling and urinary incontinence. Until recently, pain has been a largely under recognized symptom among the sequela of maladies associated with Parkinson's. Some types of pain may be resolved with dopaminergic medications while other neurogenic-related issues may require more intensive approaches, including rehabilitation. It can sometimes be difficult to identify pain related to Parkinson's versus pain due to comorbidities such as frozen shoulder or other orthopedic issues.
The presenters will delineate different treatment options for addressing different types of pain seen among individuals with Parkinson's. This session will discuss many of these recent additions to the clinical armamentarium, closing with a review of the potential efficacy of incorporating interdisciplinary teams into the treatment of for nonmotor symptoms and other issues associated with Parkinson’s.
Identify current preferred pharmacological approaches to treatment of mid-stage in advanced Parkinson’s.
Describe the prevalence of non-motor symptoms in Parkinson’s and preferred approaches to treatment.
Outline the key members of an interdisciplinary approach to treating Parkinson’s and their roles within the treatment plan.
Highlight advances in treatment that will soon be available for treatment of Parkinson’s.